Together, these results suggest that the effect of HDAC inhibition may lead to NIS promoter activation by known mechanism of increased DNA binding ability, but for certain HDACi candidate the NIS promoter activation in breast cancer cells may happen through independent (or tissue-specific) activation of factors than their thyroid counterparts. The gene discussed is HDAC9; the disease is breast carcinoma.